TY - JOUR T1 - SMARCB1/INI1 Is Diagnostically Useful in Distinguishing α-Fetoprotein-producing Gastric Carcinoma from Hepatocellular Carcinoma JF - Anticancer Research JO - Anticancer Res SP - 6865 LP - 6868 DO - 10.21873/anticanres.13061 VL - 38 IS - 12 AU - KUNIO MOCHIZUKI AU - MASATAKA KAWAI AU - TORU ODATE AU - IPPEI TAHARA AU - TOMOHIRO INOUE AU - KAZUNARI KASAI AU - TADAO NAKAZAWA AU - TETSUO KONDO Y1 - 2018/12/01 UR - http://ar.iiarjournals.org/content/38/12/6865.abstract N2 - Background/Aim: Switch/sucrose non-fermentable (SWI/SNF)-related, matrix-associated, actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1), also named integrase interactor 1, is one of the core subunit proteins in the SWI/SNF ATP-dependent chromatin remodeling complex encoded at chromosomal position 22q11.2. Complete loss of SMARCB1 expression has been reported in various malignant tumors. Immunohistochemistry has demonstrated that SMARCB1 mutation/inactivation correlates well with loss of nuclear SMARCB1 expression. This study investigated SMARCB1 expression in hepatocellular carcinomas (HCCs) and α-fetoprotein (AFP)-producing gastric carcinomas by immunohistochemistry. For comparison, SMARCB1 immunostaining in intrahepatic cholangiocarcinoma (ICC) was also performed. Materials and Methods: Thirty classical HCCs, 30 ICCs and 10 AFP-producing gastric carcinomas were analyzed. Results: Only one case of HCC had focal labeling of SMARCB1 in the nuclei. Twelve cases of ICC were immunopositive for SMARCB1, with either focal or diffuse reactivity. All AFP-producing gastric carcinomas were immunopositive for SMARCB1 in the nuclei, and the reactivity was consistently diffuse. Conclusion: SMARCB1 is a potential marker for distinguishing metastatic AFP-producing gastric carcinoma from HCC. ER -